达雷妥尤单抗单药治疗与历史对照数据在重度经治且高度难治多发性骨髓瘤患者中的比较:一项校正治疗比较
本研究通过校正治疗比较,汇总两项达雷妥尤单抗单药研究(GEN501和SIRIUS,16 mg/kg)与两个美国数据库(IMS LifeLink和OPTUM)中接受≥3线治疗或对PI和IMiD双重难治的MM患者数据,比较达雷妥尤单抗(N=148)与历史对照(N=658)的疗效。校正后OS-HR为0.33(95%CI 0.24-0.46),未校正HR为0.46(0.35-0.59),校正主要受难治状态和既往泊马度胺/卡非佐米暴露影响。结果提示达雷妥尤单抗在重度经治且高度难治MM患者中较历史对照改善OS。
要点
- 达雷妥尤单抗组与历史对照组基线特征存在差异:既往泊马度胺治疗55% vs 15%,卡非佐米41% vs 28%,三重/四重难治64% vs 14%。
- 校正后OS-HR为0.33(95%CI 0.24-0.46),未校正HR为0.46(0.35-0.59)。
- 校正的影响主要来自难治状态和既往泊马度胺/卡非佐米暴露。
核心结论
- 校正治疗比较提示,在重度经治且高度难治的多发性骨髓瘤患者中,达雷妥尤单抗较历史对照数据改善总生存。
研究设计与样本
- 校正治疗比较:汇总两项达雷妥尤单抗单药研究(16 mg/kg;GEN501和SIRIUS)与两个独立美国数据库(IMS LifeLink和OPTUM)的患者水平数据。
- 达雷妥尤单抗组N=148,历史对照组N=658;采用多因素比例风险回归模型估计相对治疗效果,并校正队列间特征失衡。
主要发现
- 达雷妥尤单抗组与历史对照组基线特征差异包括:既往泊马度胺治疗55% vs 15%,既往卡非佐米治疗41% vs 28%,三重/四重难治状态64% vs 14%。
- 校正后总生存风险比(OS-HR)为0.33(95%CI 0.24-0.46),未校正HR为0.46(95%CI 0.35-0.59)。
- 校正的影响主要驱动因素为难治状态和既往泊马度胺/卡非佐米暴露。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab is a human CD38-directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD, and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone for patients with MM who have received ≥1 prior LOT. This study compared the efficacy of daratumumab monotherapy versus historical controls through adjusted treatment comparison. Patient-level data were pooled from two daratumumab monotherapy studies (16 mg/kg; GEN501 and SIRIUS) and two independent US databases (IMS LifeLink and OPTUM), which reflect treatments used in real-world patients with MM who received ≥3 prior LOTs or were double refractory to a PI and an IMiD. Using a multivariate proportional hazards regression model, the relative treatment effect of daratumumab versus historical controls was estimated, adjusting for imbalances in characteristics between cohorts. Baseline characteristics that differed between patients treated with daratumumab (N = 148) and historical control (N = 658) were prior treatment with pomalidomide (55% vs 15%) or carfilzomib (41% vs 28%) and triple/quadruple refractory status (64% vs 14%). The adjusted overall survival-hazard ratio (OS-HR) for daratumumab versus historical control was 0.33 (95% confidence interval, 0.24-0.46) compared with 0.46 (0.35-0.59) for unadjusted HR. Impact of adjustment was mainly driven by refractory status and prior pomalidomide/carfilzomib exposure. This adjusted treatment comparison suggests that daratumumab demonstrates improved OS compared with historical control data in heavily pretreated and highly refractory MM patients.
引用
- Usmani SZ, Diels J, Ito T, et al. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017. PMID: 28474745. doi:10.1002/ajh.24781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。